Helex is taking the promise of non-viral targeted delivery and genome editing to the kidney, developing first-in-class genetic medicines for renal indications. Helex combines its proprietary kidney tropic lipid nanoparticle delivery system with the Epic-Cure(TM) 3D genome-based drug designer platform to create a robust renal franchise of precise and scalable therapeutics. Our lead asset is a mutation-agnostic, potential one-and-done therapy for Autosomal Dominant Polycystic Kidney Disease that impacts over 4 million people worldwide.
Company Details
- Employees
- 22
- Founded
- -
- Address
- 180 Varick St, New York,ny 10014,united States
- Industry
- Biotechnology
- Website
- http://www.helex.bio
- Keywords
- gene editing, renal disease, nonviral delivery, lipid nanoparticle, epigenetics, cell specific editing, genetic medicines drug design, genomic medicines.
- HQ
- New York, NY
Helex Questions
Helex's website is http://www.helex.bio
Helex's LinkedIn profile is https://www.linkedin.com/company/helexbio
Helex has
22 employees.
View email and phone details for 22
employees at Helex.
Helex's industry is
Biotechnology
Helex's top competitors are
Dragoneye,
Sign-Speak,
Unicas Biotech,
Bencos Research Solutions Pvt. Ltd.,
Cygenica Ltd.,
Rakuten India,
Yoda Diagnostics,
Anvesana,
Cell Bioengines, Inc,
Helex Healthcare Ltd. Şti.
Helex's categories are Biotechnology
Helex's founding year is 2021
